| 1382 |
National Cancer Institute |
Html |
en |
Cancer Prevention Overview (PDQ®)–Health Professional Version |
General information about cancer prevention and descriptions of the concepts used in cancer-specific prevention summaries. |
| cancer chemopreventive effect. | 0.358688 |
| female breast cancer | 0.366067 |
| Breast Cancer Screening | 0.3766 |
| evidence | 0.374057 |
| World Cancer Research | 0.371637 |
| Australian Cancer Database. | 0.371153 |
| real-world cancer risks | 0.364978 |
| prostate cancer incidence | 0.391381 |
| cancer prevention strategies | 0.427184 |
| total cancer incidence. | 0.39992 |
| postmenopausal breast cancer | 0.369903 |
| aforementioned cancer sites | 0.361157 |
| overall cancer incidence | 0.381148 |
| cancer prevention potential | 0.400219 |
| cancer risks | 0.367573 |
| cancer causation | 0.354757 |
| Prostate Cancer Prevention | 0.44176 |
| important cancer risk | 0.405276 |
| ionizing radiation | 0.400694 |
| CT scans | 0.437022 |
| cancer prevention | 0.770874 |
| major inherited cancer | 0.391979 |
| medical ionizing radiation | 0.356801 |
| Skin Cancer Prevention | 0.402533 |
| human cancer risk | 0.408538 |
|
| Lung Cancer Prevention | 0.507998 |
| male breast cancer | 0.364817 |
| radiation exposure | 0.351376 |
| PDQ cancer prevention | 0.470906 |
| high-grade prostate cancer | 0.364217 |
| Colorectal Cancer Prevention | 0.442204 |
| Endometrial Cancer Prevention | 0.388658 |
| cancer progression | 0.372078 |
| specific anatomic cancer | 0.400991 |
| Breast Cancer Prevention | 0.570001 |
| Cancer Prevention Trial | 0.382817 |
| overall cancer mortality. | 0.36635 |
| breast cancer | 0.600813 |
| colon cancer risk | 0.403854 |
| cancer prevention efforts | 0.388092 |
| cancer prevention summaries | 0.464026 |
| pancreatic cancer incidence | 0.379746 |
| cancer site | 0.376277 |
| radiation | 0.413856 |
| cancer risk | 0.665025 |
| breast cancer incidence | 0.435711 |
| lung cancer incidence | 0.378316 |
| cancer | 0.940616 |
| liver cancer | 0.392701 |
|
CLICK HERE |
| 1432 |
National Cancer Institute |
Html |
en |
Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood extracranial germ cell tumors. |
| high-risk malignant germ | 0.382627 |
| germ cell tumor | 0.468475 |
| testicular germ cell | 0.429106 |
| children | 0.370996 |
| nonseminomatous germ cell | 0.393341 |
| germ cell tumours | 0.41986 |
| Perlman EJ | 0.354009 |
| metastatic germ cell | 0.400721 |
| Cancer Group | 0.365469 |
| Cancer Res | 0.351158 |
| German germ cell | 0.402914 |
| ovarian malignant germ | 0.383572 |
| International Germ Cell | 0.398303 |
| childhood endodermal sinus | 0.354399 |
| malignant extracranial germ | 0.38557 |
| extragonadal germ cell | 0.411876 |
| Germ Cell Cancer | 0.403131 |
| Pediatric malignant germ | 0.402466 |
| childhood cancer | 0.363851 |
| eighty-one pediatric germ | 0.390298 |
| mediastinal germ cell | 0.418591 |
| sacrococcygeal germ cell | 0.389319 |
| pediatric germ cell | 0.545311 |
| et al. | 0.455659 |
|
| germ cell neoplasms | 0.392505 |
| childhood cancer mortality | 0.358219 |
| Cancer Genet Cytogenet | 0.354846 |
| extracranial germ cell | 0.411151 |
| ovarian germ cell | 0.394977 |
| United States | 0.356408 |
| poor-prognosis metastatic germ | 0.37618 |
| Germ Cell Consensus | 0.387357 |
| PUBMED Abstract | 0.47974 |
| Pediatric Oncology Group/Children | 0.350706 |
| Genes Chromosomes Cancer | 0.370613 |
| malignant germ cell | 0.446287 |
| Clin Oncol | 0.410768 |
| adolescent cancer survivors | 0.362753 |
| endodermal sinus tumors | 0.380924 |
| Schneider DT | 0.373974 |
| male germ cell | 0.395998 |
| germ cell tumors | 0.95816 |
| gonadal tumors | 0.362307 |
| primary germ cell | 0.419689 |
| cancer | 0.42182 |
| pediatric oncology group | 0.391354 |
| childhood germ cell | 0.423704 |
| germ cell cancers | 0.387284 |
|
CLICK HERE |
| 1470 |
National Cancer Institute |
Html |
en |
Gestational Trophoblastic Disease Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of gestational trophoblastic disease. |
| hydatidiform moles | 0.634979 |
| evidence | 0.648348 |
| choriocarcinoma patients | 0.633963 |
| lung metastases | 0.696902 |
| gestational trophoblastic disease | 0.762186 |
| beta-human chorionic gonadotropin | 0.712697 |
| methotrexate | 0.977049 |
| best chemotherapeutic regimen. | 0.698595 |
| weekly serum | 0.630264 |
| long-term cure rate | 0.678475 |
| intrathecal methotrexate | 0.762465 |
| 8-day regimen | 0.717809 |
| initial remission rate | 0.739354 |
| first-line regimens | 0.730221 |
| folinic acid | 0.91402 |
| complete remission rate | 0.700307 |
| cisplatin-containing regimens | 0.686171 |
| ultimate cure rates | 0.711961 |
| Cochrane systematic review | 0.696497 |
| small sample size | 0.696983 |
| dermatologic toxicity | 0.625796 |
| initial treatment | 0.625308 |
| CHAMOMA regimen | 0.706394 |
| liver metastases | 0.695394 |
|
| statistically significant increase | 0.714425 |
| systemic methotrexate | 0.81856 |
| multiagent chemotherapy | 0.710778 |
| EMA/CO regimen | 0.689015 |
| alternate regimens | 0.70432 |
| low-grade gastrointestinal toxicity | 0.724629 |
| brain metastases | 0.929548 |
| patients | 0.70324 |
| regimens | 0.73975 |
| worse CR rate | 0.705341 |
| initial regimen | 0.733597 |
| initial management | 0.736659 |
| salvage regimen | 0.720473 |
| empiric study. | 0.630801 |
| therapeutic CNS levels. | 0.6786 |
| Monthly follow-up | 0.629157 |
| dactinomycin group | 0.711146 |
| human chorionic gonadotropin | 0.959993 |
| gestational trophoblastic neoplasia | 0.961468 |
| statistically significant decrease | 0.714076 |
| best chemotherapy regimen | 0.855235 |
| 5-day regimen | 0.715118 |
| commonly used regimen | 0.784545 |
|
CLICK HERE |
| 1486 |
National Cancer Institute |
Html |
en |
Melanoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of melanoma. |
| temozolomide versus dacarbazine | 0.706064 |
| standard therapy arm | 0.513108 |
| individual treatment sections | 0.538046 |
| single-agent inhibitor | 0.443006 |
| BRAF-mutated metastatic melanoma | 0.711751 |
| Val600 BRAF-mutant melanoma | 0.627182 |
| drug targets | 0.434691 |
| clinical trial design | 0.573658 |
| Drug Administration | 0.434687 |
| primary endpoint | 0.423708 |
| DTIC | 0.525789 |
| MEK inhibitor | 0.453277 |
| rare CRs | 0.424667 |
| active moiety | 0.422545 |
| randomized trials. | 0.46852 |
| BRAF-mutant subtype | 0.57943 |
| phase III study | 0.513517 |
| important option | 0.423407 |
| phase iii trials | 0.549837 |
| oral alkylating agent | 0.523779 |
| clinical trials | 0.434562 |
| V600 mutant melanoma | 0.640167 |
| sample size | 0.421859 |
|
| palliative radiation therapy | 0.502761 |
| multicenter trial | 0.445549 |
| temozolomide group | 0.594959 |
| multiagent chemotherapy | 0.434715 |
| randomized trial | 0.479926 |
| first-line vs. | 0.432084 |
| Clin Oncol | 0.536064 |
| Combination therapies | 0.426982 |
| genomic subtypes | 0.583162 |
| superior OS | 0.42215 |
| recent registration trials | 0.531572 |
| guide clinical decision-making | 0.554726 |
| Grob JJ | 0.535846 |
| High-dose recombinant interleukin | 0.518234 |
| ECOG PS | 0.423492 |
| randomised phase | 0.46148 |
| metastatic melanoma | 0.981501 |
| previously untreated patients | 0.74564 |
| primary endpoints | 0.427198 |
| metastatic malignant melanoma | 0.829145 |
| stage IV melanoma | 0.540818 |
| U.S. Food | 0.438775 |
|
CLICK HERE |
| 1510 |
National Cancer Institute |
Html |
en |
Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of small cell lung cancer. |
| Lung Cancer Cooperative | 0.39126 |
| small-cell lung cancer | 0.985475 |
| European Lung Cancer | 0.390681 |
| chemotherapy | 0.385408 |
| Engl J Med | 0.425383 |
| American Cancer Society | 0.349857 |
| Br J Cancer | 0.382857 |
| limited-stage small-cell lung | 0.52446 |
| Lung cancer deaths | 0.390773 |
| tobacco-specific lung carcinogen | 0.37583 |
| Lung Oncology Group | 0.359221 |
| Radiat Oncol Biol | 0.383871 |
| Lung Cancer Group | 0.384497 |
| oncology group study | 0.36864 |
| poor-prognosis small-cell lung | 0.365771 |
| Natl Cancer Inst | 0.372388 |
| cancer research campaign | 0.352725 |
| Council Lung Cancer | 0.415558 |
| stage small-cell lung | 0.379153 |
| Medical Research Council | 0.386248 |
| small-cell lung carcinoma | 0.374311 |
| et al. | 0.448513 |
| Lung Cancer Working | 0.375734 |
| extensive-disease small-cell lung | 0.370168 |
| Research Council Lung | 0.400238 |
|
| Cancer Epidemiol Biomarkers | 0.349186 |
| PUBMED Abstract | 0.373095 |
| limited-disease small-cell lung | 0.382414 |
| extensive small-cell lung | 0.411565 |
| limited-stage small cell | 0.350265 |
| small cell lung | 0.655538 |
| prophylactic cranial irradiation | 0.394396 |
| disease small-cell lung | 0.396424 |
| extensive-stage small-cell lung | 0.398504 |
| lung cancer patients | 0.41432 |
| Cancer Lung Cancer | 0.412017 |
| Abstract | 0.488813 |
| Clin Oncol | 0.605439 |
| cell lung carcinoma | 0.379947 |
| Oncol Biol Phys | 0.385351 |
| untreated small-cell lung | 0.364584 |
| lung cancer risk | 0.385828 |
| advanced small-cell lung | 0.364607 |
| Low-dose lung | 0.356029 |
| cell lung cancer | 0.62237 |
| better-prognosis small-cell lung | 0.365507 |
| multiple lung nodules | 0.359952 |
| thoracic radiotherapy | 0.411609 |
| limited small-cell lung | 0.423802 |
|
CLICK HERE |
| 1601 |
National Cancer Institute |
Html |
en |
Genetics of Prostate Cancer (PDQ®)–Health Professional Version |
People with certain gene mutations (variants) are at risk for inherited prostate cancer. Learn about the hereditary prostate cancer genes, genetic testing, clinical management, psychosocial issues, and genetic counseling in this expert-reviewed summary. |
| prostate cancer-susceptibility | 0.494988 |
| hereditary prostate cancer | 0.646658 |
| prostate cancer families | 0.58011 |
| high-risk prostate cancer | 0.499108 |
| prostate cancer age | 0.510834 |
| HPCX prostate cancer | 0.495626 |
| fide prostate cancer | 0.50138 |
| race-specific prostate cancer | 0.517373 |
| potential prostate cancer | 0.502444 |
| prostate cancer treatment | 0.519074 |
| Prostate cancer clusters | 0.508795 |
| Prostate Cancer Study | 0.526793 |
| prostate cancer incidence | 0.518066 |
| familial prostate cancer | 0.542174 |
| prostate cancer cells | 0.504131 |
| prostate cancer risk | 0.754001 |
| American prostate cancer | 0.505185 |
| prostate cancer patients | 0.535381 |
| subsequent prostate cancer | 0.507929 |
| non-hereditary prostate cancer | 0.492275 |
| prostate cancer–specific death | 0.491479 |
| prostate cancer aggressiveness | 0.502657 |
| prostate cancer severity | 0.49742 |
| prostate cancer locus | 0.502621 |
| early-onset prostate cancer. | 0.497689 |
|
| early-onset prostate cancer | 0.53348 |
| prostate cancer genetics | 0.56365 |
| Utah prostate cancer | 0.495471 |
| prostate cancer probands | 0.507097 |
| prostate cancer linkage | 0.517426 |
| prostate cancer Gleason | 0.494782 |
| cancer susceptibility genes | 0.494497 |
| prostate cancer cases | 0.542257 |
| prostate cancer susceptibility | 0.699453 |
| prostate cancer studies | 0.519772 |
| prostate cancer genes | 0.510925 |
| prostate cancer pedigrees | 0.508751 |
| incident prostate cancer | 0.504028 |
| sporadic prostate cancer | 0.570825 |
| prostate cancer gene | 0.496588 |
| prostate cancer diagnosis | 0.510536 |
| multiple-case prostate cancer | 0.503665 |
| michigan prostate cancer | 0.512155 |
| prostate cancer | 0.936188 |
| family history | 0.509854 |
| new prostate cancer | 0.496227 |
| prostate cancer. | 0.520558 |
| aggressive prostate cancer | 0.511403 |
| prostate cancer risk. | 0.505722 |
|
CLICK HERE |
| 1630 |
National Cancer Institute |
Html |
en |
Aromatherapy and Essential Oils (PDQ®)–Health Professional Version |
Aromatherapy with the use of essential oils has been studied in cancer patients to help with symptom relief. Read about how massage or inhalation of essential oils have reduced symptoms in cancer patients in this expert-reviewed summary. |
| aromatherapy community | 0.523554 |
| tea tree oil | 0.469913 |
| wound care | 0.4653 |
| United States | 0.467607 |
| carrier oil | 0.505684 |
| Essential Oil Therapeutics | 0.474385 |
| psychological effects | 0.470941 |
| different oils | 0.473782 |
| aromatherapy certification | 0.522781 |
| PUBMED Abstract | 0.469015 |
| Antibacterial essential oils | 0.493066 |
| bergamot inhalation aromatherapy | 0.536518 |
| specific term aromatherapy | 0.536256 |
| aromatherapy massage group | 0.539266 |
| essential oil | 0.524 |
| aromatherapy massage | 0.663988 |
| aromatherapy report | 0.522799 |
| term aromatherapy | 0.542043 |
| aromatherapy service | 0.504027 |
| patients | 0.509871 |
| cancer patients | 0.473471 |
| Aromatherapy products | 0.521987 |
| aromatherapy intervention | 0.509122 |
|
| inhaled aromatherapy | 0.507794 |
| tea tree oils | 0.475361 |
| bergamot essential oil | 0.467339 |
| literature discuss aromatherapy | 0.521543 |
| tree oil regimen | 0.472853 |
| aromatherapy literature | 0.519173 |
| aromatherapy uses | 0.508338 |
| effects | 0.513376 |
| Different aromatherapy practitioners | 0.543887 |
| tea tree | 0.478483 |
| aromatherapy | 0.796005 |
| international aromatherapy programs | 0.535662 |
| aromatherapy remedies | 0.530036 |
| ginger essential oil | 0.475255 |
| aromatherapy massage. | 0.507361 |
| essential oil inhalation | 0.474597 |
| lavender essential oil | 0.470969 |
| essential oils | 0.95098 |
| essential oils age | 0.490389 |
| adjunctive aromatherapy massage | 0.53024 |
| aromatherapy result | 0.508296 |
| weekly aromatherapy massage | 0.530549 |
| aromatherapy sessions | 0.504333 |
|
CLICK HERE |
| 1677 |
National Cancer Institute |
Html |
en |
Childhood Astrocytomas Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood astrocytomas. |
| pediatric low-grade gliomas | 0.895421 |
| tuberous sclerosis complex | 0.221251 |
| low-grade tumors | 0.216076 |
| Metastatic Low-Grade Gliomas | 0.260825 |
| Neuro Oncol | 0.285791 |
| low-grade glioma survivors | 0.203358 |
| PUBMED Abstract | 0.35985 |
| Pediatr Blood Cancer | 0.763903 |
| brain tumors | 0.222722 |
| children | 0.324078 |
| low-grade astrocytomas | 0.305374 |
| low-grade pediatric cerebellar | 0.210061 |
| optic pathway gliomas | 0.312364 |
| pediatric high-grade gliomas | 0.220149 |
| pediatric low-grade astrocytoma | 0.249661 |
| childhood low-grade glioma | 0.299154 |
| progressive low-grade gliomas | 0.291794 |
| diencephalic low-grade astrocytomas | 0.277863 |
|
| Int J Radiat | 0.209928 |
| Radiat Oncol Biol | 0.379939 |
| childhood low-grade astrocytomas | 0.251238 |
| Abstract | 0.698357 |
| pilocytic astrocytoma | 0.38953 |
| Clin Oncol | 0.34194 |
| Oncol Biol Phys | 0.387239 |
| pediatric pilocytic astrocytomas | 0.34638 |
| pilocytic astrocytomas | 0.377237 |
| low-grade gliomas | 0.925641 |
| cord low-grade gliomas | 0.248696 |
| tumors | 0.242639 |
| recurrent low-grade gliomas | 0.279246 |
| radiation therapy | 0.261839 |
| refractory low-grade gliomas | 0.256503 |
| pediatric gliomas | 0.231368 |
| et al. | 0.71515 |
| pediatric low-grade glioma | 0.48802 |
|
CLICK HERE |
| 2034 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de próstata (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de los factores que pueden influir en el desarrollo del cáncer de próstata y sobre la investigación dirigida a la prevención de esta enfermedad. |
| Visuals Online | 0.517288 |
| hiperplasia prostática benigna | 0.934751 |
| PDQ Exámenes | 0.558681 |
| Physician Data Query | 0.625171 |
| Estados Unidos | 0.627104 |
| prevención revisa | 0.522163 |
| sistema urinario masculino | 0.572586 |
| PDQ Prevención | 0.600306 |
|
| largo plazo | 0.529195 |
| aparato reproductor masculino | 0.57627 |
| información ayuda | 0.525906 |
| National Cancer Institute | 0.530649 |
| semen.ampliar anatomÃa | 0.542589 |
| siguientes riesgos | 0.520738 |
| siguientes sumarios | 0.573516 |
| Instituto Nacional | 0.558713 |
|
CLICK HERE |
| 16694 |
National Cancer Institute |
Html |
en |
Using Trusted Resources |
Information to help people evaluate the source and credibility of health information that they find in print or online. |
| health information publications | 0.57623 |
| medical library | 0.468332 |
| health care provider | 0.525342 |
| health information | 0.816796 |
| reputable sources | 0.472899 |
| online cancer information | 0.566643 |
| research journal | 0.468961 |
| medical credentials | 0.480401 |
| Local bookstores | 0.465602 |
| web address | 0.542919 |
| Social media sites | 0.525651 |
| personal social media | 0.523002 |
| American Society | 0.463271 |
| official Facebook page | 0.525821 |
| online medical journal | 0.526189 |
| gather information | 0.496052 |
| Online health information | 0.583998 |
| trustworthy content | 0.471688 |
| credible source | 0.478584 |
| exact same kind | 0.463002 |
| educational institution | 0.468599 |
| different points | 0.462708 |
| health history | 0.475507 |
| evidence-based information | 0.519837 |
|
| sources | 0.501557 |
| research credentials | 0.469047 |
| Drug Administration | 0.463656 |
| book online | 0.475614 |
| different body | 0.465806 |
| health information online | 0.591142 |
| Twitter accounts | 0.467298 |
| National Cancer Institute | 0.533494 |
| alternative medicine | 0.466042 |
| social media | 0.640507 |
| Federal Trade Commission | 0.517205 |
| medical information | 0.510795 |
| Complementary therapies | 0.46171 |
| personal information | 0.537771 |
| new research results | 0.519971 |
| Cancer Treatment Scams | 0.525934 |
| book offer | 0.46625 |
| medical journals | 0.535182 |
| products online | 0.470366 |
| Government agencies | 0.476589 |
| social media accounts | 0.610423 |
| original source | 0.543837 |
| information | 0.948691 |
| good ways | 0.467256 |
|
CLICK HERE |